Bayer's Glyphosate Legal Battle: Supreme Court Delay and Analyst Optimism

Bayer's legal woes stem from its acquisition of Monsanto, bringing with it numerous lawsuits alleging that Roundup causes cancer. Despite settling many cases, thousands remain, posing a substantial risk. The company argues that federal law supports its position, as the EPA has deemed glyphosate safe. The Supreme Court's potential involvement could significantly alter the trajectory of these lawsuits. Meanwhile, Goldman Sachs' analyst James Quigley highlights the strength of Bayer's pharmaceutical business, overshadowed by currency impacts and the glyphosate issue. He maintains a positive outlook, setting a price target of €34. Bayer provided two forecasts to the capital market - one währungsbereinigt and one updated forecast as of March 31. They expect lower sales (€44.5 to 46.5 billion) and EBITDA (€9.2 to 9.7 billion) for the current financial year.

The central question is whether Bayer should have warned about potential health risks associated with glyphosate.

A favorable ruling could substantially reduce Bayer's legal liabilities related to glyphosate.

The ongoing lawsuits and potential settlements have negatively impacted Bayer's stock performance and overall valuation.

Do you think the Supreme Court will hear Bayer's case? How will this affect Bayer's stock? Share this article with others who need to stay ahead of this trend!